NYSE
$3.64▲ 0.28%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $133.6MShares out 36.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 9.23Pre-market26.09.23 20:108-KKey event#●●●#●●●
Armata Pharmaceuticals, Inc.Bullish
Armata Pharmaceuticals has secured $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its product candidate, AP-SA02. This brings the total cumulative non-dilutive funding for the program to $32.4 million, which the company will utilize to advance its Phase 3 clinical trial.…more
$3.64+0.28%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.14Pre-market26.09.14 20:128-KKey event
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals announced that the U.S. FDA has granted Breakthrough Therapy designation to its AP-SA02 product candidate for the treatment of complicated Staphylococcus aureus bacteremia. This designation is supported by successful Phase 1b/2a clinical trial data, and the company plans to initiate a Phase 3 study in the second half of 2026.…more
$3.64+0.28%vs prev closeView filingShare - 8.12After-hours26.08.13 05:2310-QEarnings
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals (ARMP) filed its quarterly report (10-Q) for the period ended June 30, 2026. As of August 6, 2026, the company had 37,181,979 shares of common stock outstanding, and management certified that the financial statements fairly present the company's financial condition and results of operations.…more
$3.64+0.28%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 20:10#●●●#●●●
Armata Pharmaceuticals Secures Two U.S. Patents for Phage Therapies Through 2041…more
Armata Pharmaceuticals has been granted two U.S. patents covering its phage therapy candidates, AP-SA02 and AP-PA02. These patents provide intellectual property protection for the company's proprietary technology until at least 2041.…more
$3.64+0.28%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.23Regular26.09.24 01:12
●●●●●●●● ●●●●● ●●●●●●
Armata Pharmaceuticals shares declined despite securing $3.7 million in additional non-dilutive funding from the U.S. Department of Defense for its AP-SA02 program. The stock remains in a long-term downtrend, trading significantly below key moving averages with weak momentum indicators.…more
$3.64+0.28%vs prev closeShareBenzinga - 9.23Pre-market26.09.23 20:09
●●●●●●●● ●●●●● ●●●●●●
Armata Pharmaceuticals has received an additional $3.7 million in non-dilutive funding from the U.S. Department of Defense to support the Phase 3 development of its AP-SA02 program. This brings the total cumulative funding to $32.4 million, reflecting ongoing government support for the company's clinical advancement.…more
$3.64+0.28%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report